ProMetrics Unveils Speed to Therapy Survey Results at CBI Conference

Share Article

ProMetrics, the leading specialty pharmacy data aggregation and analytics provider to the Pharmaceutical industry announces the results of their 2nd annual Speed to Therapy survey results at the 2014 CBI: Speed to Therapy conference on August 12th in Philadelphia, PA.

News Image
This year, ProMetrics has dug further into the Speed to Therapy process. We have identified key findings on the robust metrics used to define, measure, and benchmark Speed to Therapy.Marc Duey, President of ProMetrics

As part of their continued service to proactively push the industry forward, ProMetrics presented its annual Speed to Therapy survey results at the CBI Speed to Therapy conference this past August in Philadelphia, Pennsylvania. The two day conference highlighted the most current topics, discussions, and research effecting stakeholders of the Speed to Therapy process.

Speed to Therapy is one of the most important metrics in specialty pharmacy distribution of products. It is the measure of the time it takes a patient to receive medication, after the patient receives a prescription from the physician. “This year, ProMetrics has dug further into the Speed to Therapy process. We have identified key findings on the robust metrics used to define, measure, and benchmark Speed to Therapy.” said Marc Duey, President of ProMetrics. The survey included over 110 participants from across the life sciences industry. Manufacturers such as GSK, Pfizer, Bayer and Sanofi participated in the survey, along with big name Specialty Pharmacies such as Walgreens, Accredo, Diplomat and Avella. The average participant had over 18 years of industry experience. The survey was tailored toward three key stakeholders: Manufacturers, Specialty Pharmacies, and Hubs. The goal of the survey was to gain a sense for each stakeholder’s visibility and engagement in the Speed to Therapy process. The survey sought to answer several questions which have eluded prior research such as: When does the clock start and stop when measuring Speed to Therapy? Who measures it? What are the main reasons for delays? What is the industry average for Speed to Therapy? … etc.

The survey results were rather surprising and unforeseen. There were discrepancies on each stakeholder’s definition of Speed to Therapy, when the clock started/stopped, and reasonable median for the Speed to Therapy process. Take a look at ProMetric’s key findings listed below:

  •      Median STT: Majority of SP's say 1-3 Days while majority of Manufacturers say 7-9 days
  • Only 5% of Manufacturers report to the Physician, yet 50% of SP's report to the Physician
  • The majority of respondents indicated that the Hub does not result in faster STT

Download a copy of ProMetric’s FREE Survey Results

Those interested in learning more about ProMetrics research, upcoming events or service offerings, can visit To request additional information, please contact ProMetrics directly at 610-265-6344.

About ProMetrics:
ProMetrics is one of the leading data aggregators in the Life Sciences Industry, providing granular data, data analytics, and decision support for Pharmaceutical Brands and the BioPharma decision maker. With over twenty years experience, ProMetrics team are experts who work with a strong group of working partners to efficiently collect, integrate, analyze and report data. Over 140 clients have trusted ProMetrics to provide them with excellent support services.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Marc Duey
Visit website